{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:48:51Z","timestamp":1792075731179,"version":"4.4.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cell-cycle G2\u2013M phase gene UBE2C is overexpressed in various solid tumors including castration-resistant prostate cancer (CRPC). Our recent studies found UBE2C to be a CRPC-specific androgen receptor (AR) target gene that is necessary for CRPC growth, providing a potential novel target for therapeutic intervention. In this study, we showed that the G1\u2013S cell-cycle inhibitor-779 (CCI-779), an mTOR inhibitor, inhibited UBE2C mRNA and protein expression in AR-positive CRPC cell models abl and C4-2B. Treatment with CCI-779 significantly decreased abl cell proliferation in vitro and in vivo through inhibition of cell-cycle progression of both G2\u2013M and G1\u2013S phases. In addition, exposure of abl and C4-2B cells to CCI-779 also decreased UBE2C-dependent cell invasion. The molecular mechanisms for CCI-779 inhibition of UBE2C gene expression involved a decreased binding of AR coactivators SRC1, SRC3, p300, and MED1 to the UBE2C enhancers, leading to a reduction in RNA polymerase II loading to the UBE2C promoter, and attenuation of UBE2C mRNA stability. Our data suggest that, in addition to its ability to block cell-cycle G1 to S-phase transition, CCI-779 causes a cell-cycle G2\u2013M accumulation and an inhibition of cell invasion through a novel UBE2C-dependent mechanism, which contributes to antitumor activities of CCI-779 in UBE2C overexpressed AR-positive CRPC. Cancer Res; 71(14); 4866\u201376. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-4576","type":"journal-article","created":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T23:07:30Z","timestamp":1305760050000},"page":"4866-4876","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["CCI-779 Inhibits Cell-Cycle G2\u2013M Progression and Invasion of Castration-Resistant Prostate Cancer via Attenuation of UBE2C Transcription and mRNA Stability"],"prefix":"10.1158","volume":"71","author":[{"given":"Hongyan","family":"Wang","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rorick","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Wu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chiu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Thomas-Ahner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Clinton","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianben","family":"Wang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"},{"name":"Authors' Affiliations:\u20081Division of Pharmaceutical Sciences, College of Pharmacy; 2Department of Molecular and Cellular Biochemistry, 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, and 4Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,7,14]]},"reference":[{"key":"2022061702562595600_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr Rev"},{"key":"2022061702562595600_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tem.2010.01.002","article-title":"Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer","volume":"21","author":"Knudsen","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"2022061702562595600_bib3","doi-asserted-by":"crossref","first-page":"e001","DOI":"10.1621\/nrs.06001","article-title":"AR, the cell cycle, and prostate cancer","volume":"6","author":"Balk","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"2022061702562595600_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"2022061702562595600_bib5","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1172\/JCI44239","article-title":"The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression","volume":"120","author":"Sharma","year":"2010","journal-title":"J Clin Invest"},{"key":"2022061702562595600_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrm2780","article-title":"Building ubiquitin chains: E2 enzymes at work","volume":"10","author":"Ye","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061702562595600_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","article-title":"Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression","volume":"8","author":"Varambally","year":"2005","journal-title":"Cancer Cell"},{"key":"2022061702562595600_bib8","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702562595600_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nature05734","article-title":"Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation","volume":"446","author":"Reddy","year":"2007","journal-title":"Nature"},{"key":"2022061702562595600_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1083\/jcb.200906147","article-title":"Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation","volume":"188","author":"van Ree","year":"2010","journal-title":"J Cell Biol"},{"key":"2022061702562595600_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/156800909788166556","article-title":"The applicability of mTOR inhibition in solid tumors","volume":"9","author":"Konings","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"2022061702562595600_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2022061702562595600_bib13","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"2022061702562595600_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00432-009-0672-7","article-title":"Association of clinicopathological features with UbcH10 expression in colorectal cancer","volume":"136","author":"Chen","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022061702562595600_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/sj.bjc.6605122","article-title":"Validation of UBE2C protein as a prognostic marker in node-positive breast cancer","volume":"101","author":"Loussouarn","year":"2009","journal-title":"Br J Cancer"},{"key":"2022061702562595600_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1593\/tlo.09166","article-title":"Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors","volume":"3","author":"Cunha","year":"2010","journal-title":"Transl Oncol"},{"key":"2022061702562595600_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","article-title":"Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system","volume":"81","author":"Culig","year":"1999","journal-title":"Br J Cancer"},{"key":"2022061702562595600_bib18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/j.1471-4159.2007.04610.x","article-title":"Increased stem cell proliferation in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice","volume":"102","author":"Guan","year":"2007","journal-title":"J Neurochem"},{"key":"2022061702562595600_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molcel.2005.07.018","article-title":"Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking","volume":"19","author":"Wang","year":"2005","journal-title":"Mol Cell"},{"key":"2022061702562595600_bib20","first-page":"4167","article-title":"UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme","volume":"63","author":"Okamoto","year":"2003","journal-title":"Cancer Res"},{"key":"2022061702562595600_bib21","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1073\/pnas.0808300106","article-title":"Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation","volume":"106","author":"Chang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702562595600_bib22","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1128\/MCB.20.12.4188-4198.2000","article-title":"Stem-loop binding protein, the protein that binds the 3\u2032 end of histone mRNA, is cell cycle regulated by both translational and posttranslational mechanisms","volume":"20","author":"Whitfield","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2022061702562595600_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nprot.2007.25","article-title":"Establishment of human tumor xenografts in immunodeficient mice","volume":"2","author":"Morton","year":"2007","journal-title":"Nat Protoc"},{"key":"2022061702562595600_bib24","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/1078-0432.CCR-08-3007","article-title":"Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts","volume":"15","author":"Fung","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061702562595600_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molcel.2007.05.041","article-title":"A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth","volume":"27","author":"Wang","year":"2007","journal-title":"Mol Cell"},{"key":"2022061702562595600_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.ju.0000141580.30910.57","article-title":"Cell lines used in prostate cancer research: a compendium of old and new lines\u2014part 1","volume":"173","author":"Sobel","year":"2005","journal-title":"J Urol"},{"key":"2022061702562595600_bib27","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1073\/pnas.122004799","article-title":"Ordered recruitment of histone acetyltransferases and the TRAP\/Mediator complex to thyroid hormone-responsive promoters in vivo","volume":"99","author":"Sharma","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702562595600_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tibs.2010.02.004","article-title":"The human Mediator complex: a versatile, genome-wide regulator of transcription","volume":"35","author":"Taatjes","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"2022061702562595600_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrg2901","article-title":"The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation","volume":"11","author":"Malik","year":"2010","journal-title":"Nat Rev Genet"},{"key":"2022061702562595600_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"2022061702562595600_bib31","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061702562595600_bib32","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1210\/me.2007-0481","article-title":"Target gene-specific regulation of androgen receptor activity by p42\/p44 mitogen-activated protein kinase","volume":"22","author":"Agoulnik","year":"2008","journal-title":"Mol Endocrinol"},{"key":"2022061702562595600_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2003-0003","article-title":"Androgens and bone","volume":"25","author":"Vanderschueren","year":"2004","journal-title":"Endocr Rev"},{"key":"2022061702562595600_bib34","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022061702562595600_bib35","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022061702562595600_bib36","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061702562595600_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"2022061702562595600_bib38","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1128\/MCB.22.15.5575-5584.2002","article-title":"The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation","volume":"22","author":"Peng","year":"2002","journal-title":"Mol Cell Biol"},{"key":"2022061702562595600_bib39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"2022061702562595600_bib40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab"},{"key":"2022061702562595600_bib41","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.2337\/diabetes.53.11.2748","article-title":"regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis","volume":"53","author":"Kim","year":"2004","journal-title":"Diabetes"},{"key":"2022061702562595600_bib42","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1038\/onc.2008.318","article-title":"Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"2022061702562595600_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CGC.2008.n.015","article-title":"Pilot study of rapamycin in patients with hormone-refractory prostate cancer","volume":"6","author":"Amato","year":"2008","journal-title":"Clin Genitourin Cancer"},{"key":"2022061702562595600_bib44","first-page":"11","article-title":"PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells","volume":"32","author":"Kaarbo","year":"2010","journal-title":"Cell Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/14\/4866\/2653749\/4866.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/14\/4866\/2653749\/4866.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:51:40Z","timestamp":1655452300000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/14\/4866\/567713\/CCI-779-Inhibits-Cell-Cycle-G2-M-Progression-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":44,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2011,7,14]]},"published-print":{"date-parts":[[2011,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-4576","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6502523","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502523.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22389248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22389248.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]}}}